Status:
COMPLETED
Matrifen® for Therapy of Severe Chronic Pain®
Lead Sponsor:
Nycomed
Conditions:
Severe Chronic Pain
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).
Eligibility Criteria
Inclusion
- Main inclusion criteria:
- Outpatients with severe, chronic pain
- Main exclusion criteria:
- Hypersensitivity to fentanyl
- Co-administration of monoamineoxidase-inhibitors
- Pregnancy
- Respiratory depression
- Chronic obstructive pulmonary disease (COPD)
- Drug abuse
- Impairment of CNS functions
- Other criteria as defined in the Summary of Product Characteristics (Chapter 4.3)
Exclusion
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
5308 Patients enrolled
Trial Details
Trial ID
NCT00699335
Start Date
June 1 2008
Last Update
May 8 2012
Active Locations (1235)
Enter a location and click search to find clinical trials sorted by distance.
1
Nycomed Deutschland GmbH
Aalen, Germany, 73430
2
Nycomed Deutschland GmbH
Abensberg, Germany, 93326
3
Nycomed Deutschland GmbH
Adelebsen, Germany, 37139
4
Nycomed Deutschland GmbH
Ahaus, Germany, 48683